Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Maastricht

326 clinical trials in Maastricht, The Netherlands across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Maastricht at a glance
326
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

326 trials in Maastricht

Open in trial search

Chronic obstructive pulmonary disease

Recruiting

A study to evaluate the efficacy and safety of depemokimab and salbutamol sulfate in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Colorectal cancer metastatic

Recruiting

Study of Sotorasib, Panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

Breast cancer

Recruiting

Study of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:BioNTech SE

Pancreatic neuroendocrine tumour

Recruiting

A study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Exelixis Inc.

Cachexia

Recruiting

A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:VISUGROMAB
  • Sponsor:CatalYm GmbH

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:ZILEBESIRAN
  • Sponsor:Alnylam Pharmaceuticals Inc.

Cardiovascular disorder+2

Recruiting

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bi 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Gastrointestinal carcinoma

Recruiting

Study of GSK5764227 alone and in combination for patients with previously treated advanced gastrointestinal tumors that cannot be removed by surgery or have spread

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:GSK5764227
  • Sponsor:Glaxosmithkline Research & Development Limited

Chronic kidney disease+1

Recruiting

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Gastrooesophageal cancer+6

Recruiting

Study of Rinatabart Sesutecan with glatiramer acetate in patients with advanced gastrointestinal cancers

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Genmab A/S

Atrial fibrillation

Recruiting

Efficacy and Safety of BAY 3670549 in Adults with Atrial Fibrillation: A Randomized, Double‑Blind, Placebo‑Controlled Phase 2 Study

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Bayer AG

Huntington's disease

Recruiting

Efficacy and safety of votoplam in adults with Huntington’s disease: a randomized, double‑blind, placebo‑controlled Phase 3 trial

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:VOTOPLAM
  • Sponsor:Novartis Pharma AG

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Maastricht

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on colorectal cancer, breast cancer, and melanoma treatments. Studies include novel therapy combinations and personalized treatment approaches.

  • Advanced treatment protocols for metastatic conditions
  • Immunotherapy interventions
  • Diagnostic imaging improvements

Particular emphasis on targeted therapies and treatment optimization for various cancer types.

02 Chronic Disease Management

Research focusing on chronic kidney disease, fibromyalgia, and inflammatory bowel conditions. Studies evaluate new therapeutic approaches and treatment combinations.

  • Novel drug combinations
  • Disease progression monitoring
  • Quality of life improvements

Emphasis on developing effective long-term management strategies for chronic conditions.

03 Cardiovascular Studies

Investigations into peripheral arterial disease and cardiomyopathy treatments. Research includes innovative therapeutic approaches and preventive strategies.

  • Cardiovascular risk reduction
  • Treatment optimization
  • Disease prevention protocols

Focus on improving patient outcomes through targeted interventions and preventive measures.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.